About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin's lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: SPPI
- CUSIP: 84763A10
- Previous Close: $5.89
- 50 Day Moving Average: $4.97
- 200 Day Moving Average: $4.74
- 52-Week Range: $3.21 - $7.74
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.40
- P/E Growth: 0.00
- Market Cap: $467.09M
- Outstanding Shares: 79,303,000
- Beta: 1.23
- Net Margins: -34.19%
- Return on Equity: -13.92%
- Return on Assets: -7.43%
Companies Related to Spectrum Pharmaceuticals:
- Debt-to-Equity Ratio: 0.45%
- Current Ratio: 3.71%
- Quick Ratio: 3.60%
What is Spectrum Pharmaceuticals' stock symbol?
Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."
Where is Spectrum Pharmaceuticals' stock going? Where will Spectrum Pharmaceuticals' stock price be in 2017?
4 analysts have issued 1-year price targets for Spectrum Pharmaceuticals' stock. Their predictions range from $8.00 to $10.00. On average, they expect Spectrum Pharmaceuticals' share price to reach $9.50 in the next twelve months.
When will Spectrum Pharmaceuticals announce their earnings?
Spectrum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.
What are analysts saying about Spectrum Pharmaceuticals stock?
Here are some recent quotes from research analysts about Spectrum Pharmaceuticals stock:
- Jefferies Group LLC analysts commented, "SPPI is undervalued based on Rolontis' LT promise in chemotherapy-induced neutropenia. We see 50%+ share upside as Rolontis' Ph. III program is lower risk (with data in H1 2018) and we believe its profile, senior management's oncology experience, and CIN market dynamics should enable Rolontis to gain meaningful market share from Neulasta. Poziotinib in mBC/NSCLC bears watching and offers pipeline optionality. Assume at Buy and $7.50 PT." (2/10/2017)
According to Zacks Investment Research, "Shares of Spectrum have underperformed the Medical Drugs industry in the past one year. The company’s efforts to gain approval for Qapzola (bladder cancer) in the U.S. suffered a setback with the FDA issuing a Complete Response Letter (CRL) in Nov 2016. Any hiccup on the regulatory/development front could pull down the stock significantly. In addition, the company faces declining sales for most of its products due to intense competition. Generic threats also remain a major concern for the company. However, performance of newly launched multiple myeloma drug, Evomela, has been impressive. With the company inking out-licensing agreements for a number of products, it will now be able to focus on Evomela and the development of its pipeline candidates." (1/11/2017)
FBR & Co analysts commented, "This morning, before the market open, Spectrum put out a press release announcing that Evomela was approved by the FDA. Before the company put out its press release, the news of Evomela being approved by the FDA crossed the wire on Friday, March 11. Evomela was approved before its PDUFA date of May 9, 2016, so it came as somewhat of a surprise to us and investors. As a reminder, the FDA issued a CRL to Spectrum on October 23, 2015, in response to its initial NDA filing, though the CRL was not due to any clinical deficiencies identified by the FDA; rather, it was related to a Form 483 issue with one of Spectrum’s suppliers. As we previously noted, the melphalan market is only about $100 million annually." (3/15/2016)
Who owns Spectrum Pharmaceuticals stock?
Spectrum Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (6.53%), Dimensional Fund Advisors LP (2.48%), State Street Corp (2.04%), Barrow Hanley Mewhinney & Strauss LLC (0.30%), Bard Associates Inc. (0.17%) and Numeric Investors LLC (0.15%).
Who sold Spectrum Pharmaceuticals stock? Who is selling Spectrum Pharmaceuticals stock?
Spectrum Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Two Sigma Investments LP, Bard Associates Inc. and Metropolitan Life Insurance Co. NY.
Who bought Spectrum Pharmaceuticals stock? Who is buying Spectrum Pharmaceuticals stock?
Spectrum Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Russell Investments Group Ltd., Tudor Investment Corp Et Al, Comerica Bank, Thrivent Financial for Lutherans and New York State Teachers Retirement System.
How do I buy Spectrum Pharmaceuticals stock?
Shares of Spectrum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Spectrum Pharmaceuticals stock cost?
One share of Spectrum Pharmaceuticals stock can currently be purchased for approximately $5.89.